Neurology; a pain or a headache for investors?

Wed, 10/20/2010 - 6:20am
3B Nexus

Indications in neuroscience and multiple sclerosis : the past; the issues; the future. Andy Smith casts an investors eye at neurological disorders, particularly Alzheimers disease, Guillian-Barre Syndrome and multiple sclerosis. He looks at why investors find this a difficult area to predict clinical success and explores drug discovery process, interferons and new treatments.

A series of expert analysis and commentary on the Life Science sector. Join the discussion; share your views.

You need to upgrade your Flash Player!

This web site makes use of the Macromedia Flash player 8.

VIDEO PLAYER by 3b nexus

Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.